Phase 3 Trial of India's First Indigenous Dengue Vaccine, 'DengiAll,' Commences
The Phase 3 clinical trial for 'DengiAll,' India's first indigenous tetravalent dengue vaccine developed by Panacea Biotec and ICMR, has begun at KIMS, Bhubaneswar.
© Copyright 2025. All Rights Reserved by MedPath